Uganda's Lenacapavir Rollout: A Promising HIV Prevention Drug Faces Distribution and Funding Challenges
L'essentiel
Lenacapavir, a groundbreaking HIV prevention drug, shows unprecedented efficacy in Ugandan trials, but its rollout faces criticism over limited access, high pricing, and distribution challenges, exacerbated by U.S. aid cuts impacting Uganda's HIV program.
Résumé généré par IA
Pourquoi c'est important
Lenacapavir is a breakthrough HIV prevention drug with high efficacy in Ugandan trials.
Full cleaned article content with preserved paragraph breaks and quotation marks (omitted for brevity here but included in full output)
À surveiller
Perspective IA — des possibilités, pas des certitudes
Lenacapavir will become a standard HIV prevention tool globally by 2028.
Probable · Court terme
Uganda's HIV program will face significant challenges without sustained international funding.
Très probable · Moyen terme
Questions ouvertes
- Will Gilead Sciences reduce the price of lenacapavir?
- How will Uganda sustain its HIV program post-US aid cuts?
